Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039529 | 0.76 | MEN1 (0.47) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL6362644 | 0.74 | BTK (0.37) | CHRM1HRH1 | |
| SCHEMBL6753909 | 0.66 | KDM4E (0.54) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL6039844 | 0.65 | KDM4E (0.46) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL6362818 | 0.65 | MAPT (0.46) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL13325841 | 0.64 | MEN1 (0.58) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL13325874 | 0.64 | KMT2A (0.67) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL17023890 | 0.62 | MEN1 (0.65) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL13325872 | 0.62 | MEN1 (0.56) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL6795998 | 0.62 | PARP1 (0.58) | MEN1KMT2AKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664042-A1 | IMIDAZO 1,5-a PYRIDINE OR IMIDAZO 1,5-a PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | Galapagos N.V. (BE) | 2006-06-07 | — | — | EP | claimed |
| US-20050215555-A1 | Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma | BLOVITRUM AB (SE) | 2005-09-29 | — | — | US | claimed |
| WO-2005021545-A1 | IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | GALAPAGOS NV (BE) | 2005-03-10 | — | — | WO | claimed |
| EP-1664042-A1 | IMIDAZO 1,5-a PYRIDINE OR IMIDAZO 1,5-a PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | Galapagos N.V. (BE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050215555-A1 | Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma | BLOVITRUM AB (SE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005021545-A1 | IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | GALAPAGOS NV (BE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215555-A1 | Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma | HTR1A, HTR2A, HTR5A | MEN1 2115/4885KMT2A 927/4885KDM4E 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.